Accentia Biopharmaceuticals, Inc. launches CRSFungal Profile

Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) , announced today the commercial introduction of a patented, non-invasive test, CRSFungal Profile, by its specialty pharmaceuticals division, TEAMM Pharmaceuticals, to assist in the diagnosis of Chronic Sinusitis (CS) otherwise known as Chronic Rhinosinusitis (CRS). In partnership with the licensee for this patented technology, IMMCO Diagnostics Inc. (IMMCO) of Buffalo, NY, Accentia Biopharmaceuticals is making CRSFungal Profile available to ear, nose and throat (ENT) specialists and allergists nationwide.

CS is one of the most common chronic diseases suffered by Americans today, affecting an estimated 31 million patients in the US. CS is a chronic inflammatory disease of the nasal and sinus mucosa that persists for greater than three months. Long-term consequences include the formation of inflammatory polyps in the nose. The inflammation of CS results in symptoms that include nasal congestion, mouth breathing, nasal discharge, and post-nasal drip. This chronic non-infectious inflammation predisposes patients to acute exacerbations of their sinusitis due to bacterial superinfection, which requires oral antibiotic therapy. Many patients with severe disease resort to sinus surgery in an effort to reduce nasal obstruction and improve sinus drainage. Historically, the diagnosis of CS has been made based on a doctor's subjective assessment of a combination of the patients' symptoms, nasal endoscopy, and CT scan of the sinuses. There has been no confirmatory diagnostic test for the disease. Published studies by researchers at the Mayo Clinic in Rochester, Minnesota have provided substantial evidence that the underlying cause for CS is the presence of fungi, in the mucus layer of the nasal and sinus cavities. While fungi are present in the majority of the population, it is an inflammatory response in susceptible patients that causes CS. This research has led to a better understanding of the condition and

Contact: Leslie Gwinn

Page: 1 2

Related biology news :

1. FDA grants Accentia Biopharmaceuticals...
2. Accentia Biopharmaceuticals announces option agreement with Mayo
3. AutovaxID-C introduced by Accentia Biopharmaceuticals
4. Accentia Biopharmaceuticals acquires exclusive license
5. Springer launches Theoretical Ecology
6. NCRR launches national network to connect investigators based at minority institutions
7. Scientific American launches innovative new version of magazine
8. University of Arizona launches major scientific research initiative at Biosphere 2
9. Brazils first oncology biotech launches
10. University of Liverpool launches 10 million small animal teaching hospital
11. UCI launches effort to develop patient-specific stem cell lines

Post Your Comments:

(Date:9/3/2020)... ... September 03, 2020 , ... ... that an extensive third-party assessment of the company’s security practices has been completed. ... federal security regulations. The comprehensive evaluation reviewed Litmus’ processes and systems, assessing them ...
(Date:8/26/2020)... (PRWEB) , ... August 25, ... ... clinical-stage biotechnology company developing novel pharmaceuticals targeting mitochondria, in partnership with Essex ... enrolment in its pivotal U.S. Phase 3 VISTA-2 study of SkQ1 ophthalmic ...
(Date:8/26/2020)... ... August 25, 2020 , ... Modality Solutions, ... magazine’s 2020 annual Inc. 5000 list. The list is the most prestigious ranking of ... as well, and for this year’s list, reported three-year revenue growth of 71 percent. ...
Breaking Biology News(10 mins):
(Date:8/3/2020)... ... 03, 2020 , ... Introducing Ardent Animal Health – MediVet Biologics rebrands company ... Known as MediVet Biologics since its formation in 2016, the company is relaunching ... Health will build on its base of innovative therapies for osteoarthritis and cancer. ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... up to three different materials for use with CRM, neurostimulation, vascular, and related ... materials to meet specific design requirements, performance, and cost criteria; especially where solid ...
(Date:7/31/2020)... ... July 30, 2020 , ... ... today announced the release of its signature product called Beacon - a ... and other field medical professionals. , Beacon helps MSLs streamline communication ...
(Date:7/18/2020)... Ohio (PRWEB) , ... July 16, 2020 , ... ... data solutions to aid in the early detection and prevention of high-burden diseases, ... to enable US-based hospitals and healthcare organizations to utilize existing data in order ...
Breaking Biology Technology:
Cached News: